Wall Street Associates’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Wall Street Associates’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$208K	Sell	34,200 -235,100	-87%	-$1.23M	0.14%	199
2016 Q3	$1.48M	Hold	269,300	–	–	0.51%	87
2016 Q2	$1.02M	Hold	269,300	–	–	0.41%	93
2016 Q1	$743K	Hold	269,300	–	–	0.31%	106
2015 Q4	$1.53M	Sell	269,300 -236,300	-47%	-$1.44M	0.43%	79
2015 Q3	$2.68M	Sell	505,600 -355,600	-41%	-$2.75M	0.51%	66
2015 Q2	$7.15M	Sell	861,200 -13,400	-2%	-$65K	0.67%	49
2015 Q1	$4.04M	Sell	874,600 -20,200	-2%	-$65.7K	0.38%	93
2014 Q4	$2.73M	Hold	894,800	–	–	0.26%	120
2014 Q3	$2.49M	Sell	894,800 -53,700	-6%	-$195K	0.26%	117
2014 Q2	$3.86M	Sell	948,500 -1,500	-0.2%	-$6.37K	0.33%	108
2014 Q1	$5.04M	Sell	950,000 -31,958	-3%	-$179K	0.41%	89
2013 Q4	$5.45M	Buy	981,958 +26,567	+3%	+$115K	0.45%	82
2013 Q3	$4.31M	Sell	955,391 -15,717	-2%	-$70.5K	0.4%	88
2013 Q2	$4.14M	Buy	+971,108	New	+$4.88M	0.42%	79

Other funds holding SGYP

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Wall Street Associates's SGYP Position: Q4 2016 in Review

Wall Street Associates reduced its Synergy Pharmaceuticals, Inc Common Stock (SGYP) stake by 87% in Q4 2016, selling an estimated $1.23M and leaving 34,200 shares worth $208K. The position accounts for 0.14% of the portfolio, ranked #199.

Wall Street Associates first reported a position in SGYP in Q2 2013 and has held it in 15 quarters since. The position peaked at $7.15M in Q2 2015. 156 funds tracked by Wall St. Rank hold SGYP as of Q4 2016.

Wall Street Associates held 34,200 shares of Synergy Pharmaceuticals, Inc Common Stock worth $208K as of Q4 2016.
Wall Street Associates sold 235,100 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2016, an estimated $1.23M.
Synergy Pharmaceuticals, Inc Common Stock made up 0.14% of Wall Street Associates's portfolio in Q4 2016, its #199 holding.
Wall Street Associates first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and has held it in 15 quarters since.
Wall Street Associates's Synergy Pharmaceuticals, Inc Common Stock position peaked at $7.15M in Q2 2015.
156 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.